A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (NCT05050942)
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Cancer Center (MCCC) - Phoenix — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (86 Sites)
Showing the first 25 of 86 sites.
- Mayo Clinic Cancer Center (MCCC) - Phoenix — Phoenix, Arizona
- UCLA Ahmanson Biological Imaging Center — Santa Monica, California
- Rocky Mountain Cancer Centers - Denver - Midtown — Denver, Colorado
- Mayo Clinic Hospital - Florida — Jacksonville, Florida
- University of Kentucky (UK) - Markey Cancer Center — Lexington, Kentucky
- East Jefferson General Hospital — Metairie, Louisiana
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Texas Oncology - Austin — Austin, Texas
- Texas Oncology - Dallas — Dallas, Texas
- The University of Texas - MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - McAllen — McAllen, Texas
- Texas Oncology - San Antonio Northeast — San Antonio, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- GenesisCare - North Shore — Alexandria,
- Fiona Stanley Hospital — Murdoch,
- Cliniques Universitaires Saint-Luc — Brussels,
- Hôpital Erasme — Brussels,
- Antwerp University Hospital — Edegem,
- Algemeen Ziekenhuis Maria Middelares — Ghent,
- AZ Nikolaas — Sint-Niklaas,
- London Health Sciences Centre — London,
- Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital — Montreal,
- Jewish General Hospital — Montreal,
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastro-enteropancreatic Neuroendocrine Tumor
Explore by condition: All Gastro-enteropancreatic Neuroendocrine Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.